Best supportive care for the anaemia of myelodysplasia: inclusion of recombinant erythropoietin therapy?

This publication has 9 references indexed in Scilit:

• Long-term follow-up of 18 patients with myelodysplastic syndromes responding to recombinant erythropoietin treatment
  Leukemia Research, 2000
• Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony‐stimulating factor and erythropoietin
  British Journal of Haematology, 2000
• Cost Effectiveness, Quality-Adjusted Life-Years and Supportive Care
  PharmacoEconomics, 1999
• A randomized double‐blind placebo‐controlled study with subcutaneous recombinant human erythropoietin in patients with low‐risk myelodysplastic syndromes
  British Journal of Haematology, 1998
• Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.
  Journal of Clinical Oncology, 1998
• Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia
  British Journal of Cancer, 1998
• Erythroid response to treatment with G‐CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model
  British Journal of Haematology, 1997
• Cost Comparison of Recombinant Human Erythropoietin and Blood Transfusion in Cancer Chemotherapy-Induced Anemia
  Annals of Pharmacotherapy, 1997
• Efficacy of erythropoietin in the myelodysplastic syndromes: a meta‐analysis of 205 patients from 17 studies
  British Journal of Haematology, 1995